196 related articles for article (PubMed ID: 26676746)
1. Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.
Li M; Kales SC; Ma K; Shoemaker BA; Crespo-Barreto J; Cangelosi AL; Lipkowitz S; Panchenko AR
Cancer Res; 2016 Feb; 76(3):561-71. PubMed ID: 26676746
[TBL] [Abstract][Full Text] [Related]
2. Cbl interacts with multiple E2s in vitro and in cells.
Liyasova MS; Ma K; Voeller D; Ryan PE; Chen J; Klevit RE; Lipkowitz S
PLoS One; 2019; 14(5):e0216967. PubMed ID: 31120930
[TBL] [Abstract][Full Text] [Related]
3. Negative regulation of EGFR-Vav2 signaling axis by Cbl ubiquitin ligase controls EGF receptor-mediated epithelial cell adherens junction dynamics and cell migration.
Duan L; Raja SM; Chen G; Virmani S; Williams SH; Clubb RJ; Mukhopadhyay C; Rainey MA; Ying G; Dimri M; Chen J; Reddi AL; Naramura M; Band V; Band H
J Biol Chem; 2011 Jan; 286(1):620-33. PubMed ID: 20940296
[TBL] [Abstract][Full Text] [Related]
4. Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.
Tan YC; Mirzapoiazova T; Won BM; Zhu L; Srivastava MK; Vokes EE; Husain AN; Batra SK; Sharma S; Salgia R
Sci Rep; 2017 Aug; 7(1):9192. PubMed ID: 28835699
[TBL] [Abstract][Full Text] [Related]
5. Suppressed expression of Cbl-b by NF-κB mediates icotinib resistance in EGFR-mutant non-small-cell lung cancer.
Zhang T; Zheng C; Hou K; Wang J; Zhang Y; Fan Y; Zhao H; Qu X; Liu Y; Kang J; Che X; Hu X
Cell Biol Int; 2019 Feb; 43(2):98-107. PubMed ID: 29972257
[TBL] [Abstract][Full Text] [Related]
6. Flotillin-2 regulates epidermal growth factor receptor activation, degradation by Cbl-mediated ubiquitination, and cancer growth.
Wisniewski DJ; Liyasova MS; Korrapati S; Zhang X; Ratnayake S; Chen Q; Gilbert SF; Catalano A; Voeller D; Meerzaman D; Guha U; Porat-Shliom N; Annunziata CM; Lipkowitz S
J Biol Chem; 2023 Jan; 299(1):102766. PubMed ID: 36470425
[TBL] [Abstract][Full Text] [Related]
7. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.
Sanada M; Suzuki T; Shih LY; Otsu M; Kato M; Yamazaki S; Tamura A; Honda H; Sakata-Yanagimoto M; Kumano K; Oda H; Yamagata T; Takita J; Gotoh N; Nakazaki K; Kawamata N; Onodera M; Nobuyoshi M; Hayashi Y; Harada H; Kurokawa M; Chiba S; Mori H; Ozawa K; Omine M; Hirai H; Nakauchi H; Koeffler HP; Ogawa S
Nature; 2009 Aug; 460(7257):904-8. PubMed ID: 19620960
[TBL] [Abstract][Full Text] [Related]
8. CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.
Lv K; Jiang J; Donaghy R; Riling CR; Cheng Y; Chandra V; Rozenova K; An W; Mohapatra BC; Goetz BT; Pillai V; Han X; Todd EA; Jeschke GR; Langdon WY; Kumar S; Hexner EO; Band H; Tong W
Genes Dev; 2017 May; 31(10):1007-1023. PubMed ID: 28611190
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for ubiquitin-mediated dimerization and activation of the ubiquitin protein ligase Cbl-b.
Peschard P; Kozlov G; Lin T; Mirza IA; Berghuis AM; Lipkowitz S; Park M; Gehring K
Mol Cell; 2007 Aug; 27(3):474-85. PubMed ID: 17679095
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptors with tyrosine kinase domain mutations exhibit reduced Cbl association, poor ubiquitylation, and down-regulation but are efficiently internalized.
Padrón D; Sato M; Shay JW; Gazdar AF; Minna JD; Roth MG
Cancer Res; 2007 Aug; 67(16):7695-702. PubMed ID: 17699773
[TBL] [Abstract][Full Text] [Related]
11. Targeting CDC34 E2 ubiquitin conjugating enzyme for lung cancer therapy.
Zhang S; Sun Y
EBioMedicine; 2020 Apr; 54():102718. PubMed ID: 32268269
[No Abstract] [Full Text] [Related]
12. E2-c-Cbl recognition is necessary but not sufficient for ubiquitination activity.
Huang A; de Jong RN; Wienk H; Winkler GS; Timmers HT; Boelens R
J Mol Biol; 2009 Jan; 385(2):507-19. PubMed ID: 18996392
[TBL] [Abstract][Full Text] [Related]
13. c-Cbl-mediated neddylation antagonizes ubiquitination and degradation of the TGF-β type II receptor.
Zuo W; Huang F; Chiang YJ; Li M; Du J; Ding Y; Zhang T; Lee HW; Jeong LS; Chen Y; Deng H; Feng XH; Luo S; Gao C; Chen YG
Mol Cell; 2013 Feb; 49(3):499-510. PubMed ID: 23290524
[TBL] [Abstract][Full Text] [Related]
14. Cbl-c ubiquitin ligase activity is increased via the interaction of its RING finger domain with a LIM domain of the paxillin homolog, Hic 5.
Ryan PE; Kales SC; Yadavalli R; Nau MM; Zhang H; Lipkowitz S
PLoS One; 2012; 7(11):e49428. PubMed ID: 23145173
[TBL] [Abstract][Full Text] [Related]
15. Somatic mutations lead to an oncogenic deletion of met in lung cancer.
Kong-Beltran M; Seshagiri S; Zha J; Zhu W; Bhawe K; Mendoza N; Holcomb T; Pujara K; Stinson J; Fu L; Severin C; Rangell L; Schwall R; Amler L; Wickramasinghe D; Yauch R
Cancer Res; 2006 Jan; 66(1):283-9. PubMed ID: 16397241
[TBL] [Abstract][Full Text] [Related]
16. Additional serine/threonine phosphorylation reduces binding affinity but preserves interface topography of substrate proteins to the c-Cbl TKB domain.
Sun Q; Jackson RA; Ng C; Guy GR; Sivaraman J
PLoS One; 2010 Sep; 5(9):e12819. PubMed ID: 20877636
[TBL] [Abstract][Full Text] [Related]
17. δ-Catenin Increases the Stability of EGFR by Decreasing c-Cbl Interaction and Enhances EGFR/Erk1/2 Signaling in Prostate Cancer.
Shrestha N; Shrestha H; Ryu T; Kim H; Simkhada S; Cho YC; Park SY; Cho S; Lee KY; Lee JH; Kim K
Mol Cells; 2018 Apr; 41(4):320-330. PubMed ID: 29629558
[TBL] [Abstract][Full Text] [Related]
18. Mutant epidermal growth factor receptor undergoes less protein degradation due to diminished binding to c-Cbl.
Hosaka T; Inoue F; Ando K; Ishida H; Kusumoto S; Sugiyama T; Shirai T; Okuda K; Hirose T; Ohnishi T; Horichi N; Saijo N; Adachi M; Nakadate T; Kuroki T; Ohmori T
Anticancer Res; 2007; 27(4B):2253-63. PubMed ID: 17695511
[TBL] [Abstract][Full Text] [Related]
19. E3 ubiquitin ligases Cbl-b and c-Cbl downregulate PD-L1 in EGFR wild-type non-small cell lung cancer.
Wang S; Xu L; Che X; Li C; Xu L; Hou K; Fan Y; Wen T; Qu X; Liu Y
FEBS Lett; 2018 Feb; 592(4):621-630. PubMed ID: 29364514
[TBL] [Abstract][Full Text] [Related]
20. Loss of function Cbl-c mutations in solid tumors.
Daniels SR; Liyasova M; Kales SC; Nau MM; Ryan PE; Green JE; Lipkowitz S
PLoS One; 2019; 14(7):e0219143. PubMed ID: 31260484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
